Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

660626.pdf (2.32 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-04-25

Llicència de publicació

cc-by (c) Garcia-Recio, S. et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/97661

Biological and Pharmacological aspects of the NK1-Receptor.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1155/2015/495704

Resum

The neurokinin 1 receptor (NK-1R) is the main receptor for the tachykinin family of peptides. Substance P (SP) is the major mammalian ligand and the one with the highest affinity. SP is associated with multiple processes: hematopoiesis, wound healing, microvasculature permeability, neurogenic inflammation, leukocyte trafficking, and cell survival. It is also considered a mitogen, and it has been associated with tumorigenesis and metastasis. Tachykinins and their receptors are widely expressed in various human systems such as the nervous, cardiovascular, genitourinary, and immune system. Particularly, NK-1R is found in the nervous system and in peripheral tissues and are involved in cellular responses such as pain transmission, endocrine and paracrine secretion, vasodilation, and modulation of cell proliferation. It also acts as a neuromodulator contributing to brain homeostasis and to sensory neuronal transmission associated with depression, stress, anxiety, and emesis. NK-1R and SP are present in brain regions involved in the vomiting reflex (the nucleus tractus solitarius and the area postrema). This anatomical localization has led to the successful clinical development of antagonists against NK-1R in the treatment of chemotherapy-induced nausea and vomiting (CINV). The first of these antagonists, aprepitant (oral administration) and fosaprepitant (intravenous administration), are prescribed for high and moderate emesis.

Matèries

Pèptids, Sistema nerviós, Farmacologia molecular, Biologia molecular

Matèries (anglès)

Peptides, Nervous system, Molecular pharmacology, Molecular biology

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

GARCIA RECIO, Susana and GASCÓN, Pere. Biological and Pharmacological aspects of the NK1-Receptor. BioMed Research International. 2015. Vol. 2015, num. 495704. ISSN 2314-6133. [consulted: 26 of August of 2026]. Available at: https://hdl.handle.net/2445/97661

Exportar metadades

JSON - METS

Compartir registre